{
    "clinical_study": {
        "@rank": "166405", 
        "arm_group": [
            {
                "arm_group_label": "gemfibrozil + ASP3652", 
                "arm_group_type": "Experimental", 
                "description": "Multiple doses of gemfibrozil and single dose of ASP3652"
            }, 
            {
                "arm_group_label": "ASP3652 + repaglinide", 
                "arm_group_type": "Experimental", 
                "description": "Multiple doses of ASP3652 and  the single dose of repaglinide"
            }
        ], 
        "brief_summary": {
            "textblock": "ASP3652 is being investigated as a novel treatment for chronic pelvic pain. This is a\n      two-part study to investigate the drug-drug potential of ASP3652.\n\n      Part I of the study evaluates the effect of gemfibrozil twice daily on the  single dose of\n      ASP3652.\n\n      Part 2 evaluates the effect of multiple doses of ASP3652 twice daily on the  single dose of\n      repaglinide.\n\n      Subjects participating in one part of the study may not participate in the other part."
        }, 
        "brief_title": "A Study to Assess the Effect of Multiple Doses of Gemfribozil on a Single Dose of ASP3652, and to Assess the Effects of Multiple Doses of ASP3652 on a Single Dose of Repaglinide in the Body of Healthy Subjects", 
        "completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Drug-Drug Interaction (DDI)", 
            "Healthy Subjects"
        ], 
        "detailed_description": {
            "textblock": "Part 1:\n\n      On Day 1, a single dose of ASP3652 is administered. After a wash-out period of 3 days, bid\n      (twice daily) dosing of gemfibrozil starts on Day 4 and continues for 7 days until Day 10.\n      On Day 8 (the 5th day of gemfibrozil administration), a single dose of ASP3652 is\n      administered one hour after the morning dose of gemfibrozil.\n\n      Part 2:\n\n      On Day 1, a single dose of repaglinide is administered. After a wash-out period of 3 days,\n      bid dosing of ASP3652 starts on Day 4 and continues for 7 days until Day 10. On Day 8 (the\n      5th day of ASP3652 administration), a single dose of repaglinide is administered one hour\n      after the morning dose of ASP3652."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is white and of Caucasian origin.\n\n          -  Body Mass Index more than or equal to 18.5 and less than 30.0 kg/m2.\n\n          -  Male subjects must agree to practice an effective contraceptive method with female\n             sexual partners to prevent pregnancy.\n\n        Exclusion Criteria:\n\n          -  Known or suspected hypersensitivity to ASP3652, repaglinide and/or gemfibrozil, or\n             any components of the formulation used.\n\n          -  Any of the liver function tests (ALT, AST, \u03b3-GT, TBL and ALP) above the upper limit\n             of normal. In such case the sample may be repeated once.\n\n          -  Regular use of any inducer of metabolism (e.g. barbiturates, Rifampicin) in the 3\n             months prior to admission to the Clinical Unit."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01797198", 
            "org_study_id": "3652-CL-0006", 
            "secondary_id": "2011-002874-21"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "gemfibrozil + ASP3652", 
                    "ASP3652 + repaglinide"
                ], 
                "description": "Oral", 
                "intervention_name": "ASP3652", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "gemfibrozil + ASP3652", 
                "description": "Oral", 
                "intervention_name": "Gemfibrozil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ASP3652 + repaglinide", 
                "description": "Oral", 
                "intervention_name": "Repaglinide", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemfibrozil", 
                "Repaglinide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Phase I", 
            "ASP3652", 
            "Gemfibrozil", 
            "Repaglinide", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "February 20, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Harrow", 
                    "country": "United Kingdom", 
                    "zip": "HA1 3U"
                }, 
                "name": "PAREXEL Early Phase Clinical Unit"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open Label, Drug-drug Interaction Study to Assess the Effect of Multiple Doses of Gemfibrozil on the Single Dose Pharmacokinetics of ASP3652 and to Assess the Effect of Multiple Doses of ASP3652 on the Single Dose Pharmacokinetics of Repaglinide", 
        "overall_official": {
            "affiliation": "Astellas Pharma Europe B.V.", 
            "last_name": "Study Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United Kingdom: National Health Service", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Part 1: Maximum concentration (Cmax), AUClast and AUCinf", 
                "measure": "Effect of multiple doses of gemfibrozil on the Pharmacokinetics (PK) of a single dose of ASP3652 (plasma) and metabolites H1/H2/H3", 
                "safety_issue": "No", 
                "time_frame": "Days 1 - 11"
            }, 
            {
                "description": "Part 2: Cmax, AUClast, AUCinf, and the ratio AUC(M4) / AUC(repaglinide)", 
                "measure": "Effect of multiple doses of ASP3652 on the PK of a single dose of repaglinide and metabolite M4 (plasma)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 - 10"
            }, 
            {
                "description": "Both Parts: Vital signs, physical examination, adverse events, electrocardiogram, clinical laboratory assessments, body temperature, Bond and Lader Visual Analogue Scale (VAS) questionnaire, Physician's Withdrawal Checklist (PWC)", 
                "measure": "Assess the safety of single and multiple doses of ASP3652 alone and in combination with gemfibrozil or repaglinide", 
                "safety_issue": "No", 
                "time_frame": "Screening - End of Study Visit (7-14 days after (early) discharge)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01797198"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Part 1: tmax, tlag, t1/2, Vz/F, CL/F, Cmax, morning and evening Ctrough, tmax, AUCtau and CL/F", 
                "measure": "Effect of multiple doses of gemfibrozil on the PK of a single dose of ASP3652 (plasma),  metabolites H1/H2/H3 and Parent gemfibrozil and gemfibrozil-1-O-\u00df-glucuronide (plasma)", 
                "safety_issue": "No", 
                "time_frame": "Days 1-11"
            }, 
            {
                "description": "Part 2: tmax, tlag, t1/2, Vz/F, CL/F, Cmax, morning and evening Ctrough, tmax, AUCtau and CL/F", 
                "measure": "Effect of multiple doses of ASP3652 on the PK of a single dose of repaglinide", 
                "safety_issue": "No", 
                "time_frame": "Days 1-10"
            }, 
            {
                "description": "Part 2: Baseline blood glucose concentration, minimum blood glucose concentration, and mean blood glucose concentration from 0 to 9h after dosing of repaglinide", 
                "measure": "Effect of ASP3652 on the Pharmacodynamics (PD) of repaglinide by comparing the effect of repaglinide on blood glucose levels in the presence and absence of ASP3652", 
                "safety_issue": "No", 
                "time_frame": "Days 1-10"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Europe B.V.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}